Literature DB >> 3325257

Side effects of ofloxacin in clinical trials and in postmarketing surveillance.

G Jüngst1, R Mohr.   

Abstract

Data derived from clinical trials of ofloxacin in 15,962 patients show that the incidence rate of adverse drug events was 4.27 per 100 patients. Symptoms were generally mild and related to the gastrointestinal tract, nervous system or hypersensitivity reactions in rank order. On the other hand, spontaneous reports obtained during postmarketing surveillance involving 1.5 million patients showed that the most frequent adverse drug events were related to the nervous system; next in order of frequency were hypersensitivity reactions and gastrointestinal symptoms. A comparison of the data obtained from clinical trials and postmarketing surveillance revealed no change in the favourable overall benefit:risk ratio of ofloxacin. Possible reasons for the different patterns of adverse drug events are discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3325257     DOI: 10.2165/00003495-198700341-00031

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  3 in total

1.  The Food and Drug Administration algorithm. Special workshop--regulatory.

Authors:  W M Turner
Journal:  Drug Inf J       Date:  1984

2.  Adverse drug reactions. A critical review.

Authors:  F E Karch; L Lasagna
Journal:  JAMA       Date:  1975-12-22       Impact factor: 56.272

3.  Under-reporting of adverse drug reactions.

Authors:  W H Inman
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-04
  3 in total
  17 in total

Review 1.  Evaluation of safety and tolerance in clinical trials with antimicrobial agents.

Authors:  H Lode; R Stahlmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

2.  [Documentation and assessment of adverse drug effects with ofloxacin as an example].

Authors:  B Esch; N Paeschke; W Christ; G Kreutz
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 3.  Tolerability of fluoroquinolone antibiotics. Past, present and future.

Authors:  P Ball; G Tillotson
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

4.  Fatal vasculitis associated with ofloxacin.

Authors:  J L Pace; P Gatt
Journal:  BMJ       Date:  1989-09-09

5.  Hypersensitivity vasculitis due to ofloxacin.

Authors:  D Huminer; J D Cohen; R Majadla; S Dux
Journal:  BMJ       Date:  1989-07-29

Review 6.  Fluoroquinolones. Adverse reactions during clinical trials and postmarketing surveillance.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1989-08-25

Review 7.  Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.

Authors:  S V Onrust; H M Lamb; J A Balfour
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

8.  Levofloxacin-induced delirium.

Authors:  Gleb Slobodin; Nizar Elias; Natalia Zaygraikin; Muhammad Sheikh-Ahmad; Sergiu Sabetay; Boaz Weller; Majed Odeh
Journal:  Neurol Sci       Date:  2009-02-03       Impact factor: 3.307

9.  Accidental overdose of intravenous ofloxacin with benign outcome.

Authors:  R B Kohler; N Arkins; K J Tack
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

10.  Ofloxacin compared with chloramphenicol in the management of external ocular infection.

Authors:  A J Bron; G Leber; S N Rizk; H Baig; A R Elkington; G R Kirkby; C Neoh; A Harden; T Leong
Journal:  Br J Ophthalmol       Date:  1991-11       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.